An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.
Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.
Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.
Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.